Bariatry News
-
Vantage Welcomes Roczen!
We are delighted to welcome Roczen to the community of healthcare organisations leveraging Vantage Software! We look forward to working together and helping them deliver exceptional care and support to those living with chronic conditions. Book a Free Demo ...
-
CD BioSciences Launches New Services to Study Catabolism in Diabetes
CD BioSciences, a US-based CRO serving the global life science research community, has announced the launch of its new Catabolism research services, which offer researchers a comprehensive range of tools and resources to investigate the role of catabolism in the development and progression of diabetes. Metabolism describes a series of life-sustaining chemical reactions in an organism that convert ...
-
Alfa Chemistry Offers Varieties of Marine Biomaterials for Use in Biomedicine, Cosmetics and Nutraceuticals
The US-located chemical supplier Alfa Chemistry has recently unveiled its wide range of marine biomaterials, opening new possibilities in the fields of biomedicine, cosmetics, and nutraceuticals. With an extensive collection of marine polysaccharides, oligosaccharides, bioactive peptides, marine oils, and microalgae powders, researchers and industries alike can explore the potential of marine ...
-
Expanding Possibilities: CD Formulation Unveils Comprehensive Selection of 90+ Active Pharmaceutical Ingredients
Emerging as an excipient supplier and a contract research organization (CRO), CD Formulation has flourished in the pharmaceutical industry. The company recently unveiled its latest collection of over 90 active pharmaceutical ingredients (APIs) to the scientific community. These APIs will serve as essential components in the formulation of various drugs. APIs are the primary components of ...
-
Analysis of the cryolipolysis slimming machine advantages and disadvantages
Cryolipolysis is a medical aesthetic technique that uses freezing to break down excess fat in the body to achieve a slimming effect. This technique has a great popularity and many people feel confident and beautiful because of the success of this technique to lose weight. As we all know, the medical aesthetic industry has always been a hot industry and cryolipolysis beauty machine as a technique ...
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Creative Proteomics Metabolomics Expands Service Offering with the Launch of Gut Microbiota Metabolomics Solution
Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. Creative Proteomics Metabolomics announced the launch of the Gut Microbiota Metabolomics Service, aiming to detect the dynamic changes in enterobacterial metabolites and clearly ...
-
Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities Global Biopharma ...
-
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD). The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a ...
-
Structure-Based Search for Novel Antihypercholestrolemic Agents
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are ...
-
Development of Oral Small Molecule PCSK9 Antagonist
Abstract Project Summary Abstract The epidemic of cardiovascular diseaseCVDis a global phenomenon that remains the number one cause of death throughout the worldkilling nearlymillion people per yeara number that is expected to grow tomillion byA high cholesterol level is well known risk factors for heart diseaseAlthough blood cholesterol can be lowered using a number of marketed drugsof which ...
-
Novel Modulators of LDL Metabolism
DESCRIPTION provided by applicant Heart disease is the leading cause of death for both men and women in the US accounting for nearly of all annual deaths A high cholesterol level is well known risk factors for heart disease Although blood cholesterol can be lowered using a number of marketed drugs of which statins are the leading drugs only of patients taking these drugs are achieving the low ...
-
World Diabetes Day
An estimated 415 million people are living with diabetes in the world. Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. If left untreated, this can lead to serious complications such as heart attack, stroke, obesity, eye ...
-
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results ...
By CohBar, Inc.
-
Creative Enzymes Launches Raw Materials for Manufacturing Diagnostic Kits
Creative Enzymes, a worldwide leading company in diagnostic enzymes manufacturing and supply, is committed to providing customers with diverse enzyme products and custom enzyme-related services for medical and research diagnosis. Recently, Creative Enzymes launched the raw materials for manufacturing Diagnostic Kits. The raw materials provided by Creative Enzymes include enzymes for cholesterol ...
-
Ezisurg Medical presented at the European Bariatric Endoscopic Surgery Congress
On 23-24th September, 2021, the annual European Bariatric Endoscopic Surgery Trends (BEST) was successfully held in Montpellier, France. The BEST congress adopted a unique mode of online and offline access, bringing global experts and scholars together to discuss the cutting-edge progress in the field of bariatric surgery. Ezisurg Medical was honored to become the platinum partner of BEST, and ...
-
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release ...
By CohBar, Inc.
-
Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion. “It is with great pleasure that I ...
-
Alfa Chemistry Announces the Launch of Extracted Peptides
Demonstrating competence in peptide R&D, production, and sales integration, the US-based chemical supplier Alfa Chemistry recently announced the launch of its peptide product line for researchers across the globe. After this move, a wide range of high-quality extracted peptides, including hydrolyzed protein peptides, fish collagen peptides, marine fish oligopeptides, oyster peptides, sea ...
-
Why Innovation in Blood Testing Matters
Why should payers care about clinical laboratory testing? Clinical laboratory testing plays an essential role in the delivery of health care. From early detection and diagnosis of disease to individualized treatment plans based on a person’s unique biology, medical care depends on accurate and timely health data. Seventy percent of medical decisions depend on lab test results, so making ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you